0353 GMT - President Trump's "Liberation Day" tariffs are likely not a big concern for China's healthcare industry, Jefferies analysts say in a research note. Drugs and active pharmaceutical ingredients are exempt from tariffs, and even if Trump imposed any tariffs in the future, most Chinese biotech companies have U.S. partners that are not considered exporters, they say. Contract drug makers, such as the WuXi companies, are in exempt categories as well, they note. "If the exemption were canceled, the tariff would apply to all non-U.S. competitors, while Chinese players would retain cost and efficiency advantages," they say. Medical equipment makers are subject to 54% tariffs, but the analysts reckon the impact will be manageable, as the Chinese makers, such as Mindray Medical International, have low sales exposure to the U.S. (sherry.qin@wsj.com)
(END) Dow Jones Newswires
April 02, 2025 23:53 ET (03:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。